

Stomatin modulates adipocyte differentiation through ERK pathway and regulates lipid droplet growth and function

Shao-Chin Wu

National Yang-Ming University/Biophotonics <https://orcid.org/0000-0002-1960-1581>

Yuan-Ming Lio

National Yang-Ming University/Microbiology and Immunology

Jui-Hao Lee

National Yang-Ming University/Taiwan International Graduate Program in Molecular Medicine

Chin-Yau Chen

National Yang-Ming University Hospital

Tung-Wei Chen

National Yang-Ming University

Hong-Wen Liu

National Yang-Ming University

Wei-Nan Lian

National Yang-Ming University

Wei-Ju Lin

National Yang-Ming University/Cancer Progression Research Center

Chih-Yung Yang

Taipei City Hospital

Chien-Yi Tung

National Yang-Ming University/Cancer Progression Research Center

Chi-Hung Lin (✉ linch@ym.edu.tw)

National Yang-Ming University/Biophotonics

Article

Keywords: Stomatin, adipocyte differentiation, ERK pathway, lipid droplet growth and function

Posted Date: November 10th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-94915/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Nature Communications on July 19th, 2022. See the published version at <https://doi.org/10.1038/s41467-022-31825-z>.

1 **Stomatin modulates adipocyte differentiation through ERK** 2 **pathway and regulates lipid droplet growth and function**

3 Shao-Chin Wu¹, Yuan-Ming Lio², Jui-Hao Lee³, Chin-Yau Chen⁴, Tung-Wei Chen¹,
4 Hong-Wen Liu⁵, Wei Nan Lian², Wei-Ju Lin⁶ Chih-Yung Yang⁷, Chien-Yi Tung^{6#}, Chi-
5 Hung Lin^{1,2,6,8*}

6 1. Institute of Biophotonics, National Yang-Ming University, Taipei, Taiwan

7 2. Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan

8 3. Taiwan International Graduate Program in Molecular Medicine, National Yang-Ming University
9 and Academia Sinica, Taipei, Taiwan

10 4. National Yang-Ming University Hospital, Yilan, Taiwan

11 5. Chong Hin Loon Memorial Cancer and Biotherapy Research Center, Taipei, Taiwan

12 6. Cancer Progression Research Center, National Yang-Ming University, Taipei, Taiwan

13 7. Department of Education and Research, Taipei City Hospital, Taipei, Taiwan

14 8. Department of Biological Science and Technology, National Chiao-Tung University, Hsinchu,
15 Taiwan

16 ***Correspondence**

17 **Chi-Hung Lin, MD, ph.D.**

18 Institute of Biophotonics, National Yang-Ming University, Taipei, Taiwan

19 Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan

20 Cancer Progression Research Center, National Yang-Ming University, Taipei, Taiwan

21 Department of Biological Science and Technology, National Chiao-Tung University, Hsinchu,
22 Taiwan

23 No.155, Sec.2, Linong Street, Taipei, 112 Taiwan (ROC)

24 Telephone: +886-2-28267000#5613

25 E-mail: linch@ym.edu.tw

26 **#Co-correspondence**

27 **Chien-Yi Tung, ph.D.**

28 Cancer Progression Research Center, National Yang-Ming University, Taipei, Taiwan

29 No.155, Sec.2, Linong Street, Taipei, 112 Taiwan (ROC)

30 Telephone: +886-2-28267000#5678

31 E-mail: E-mail: Cytung@ym.edu.tw

32

33 **Abstract**

34 Controlling fatty acid uptake, lipid production and storage, and metabolism of lipid
35 droplets (LDs), are closely related to lipid homeostasis, adipocyte hypertrophy and
36 obesity. We report here that stomatin, a major constituent of the lipid raft, participate
37 in adipogenesis and lipogenesis by preferentially recruiting effectors, such as perilipin
38 for LD fusion or transporters for fatty acid uptake. Adipocyte-like cells having increased
39 stomatin expressions exhibit higher levels of fatty acid uptake and LD growth or
40 enlargements. Moreover, transgenic mice fed with a high-fat diet showed increased
41 stomatin expression that facilitated progression of obesity and caused insulin
42 resistance and hepatic impairments. Conversely, inhibitions of stomatin by gene
43 knockdown or pharmacological treatments could block not only LD growth but also
44 adipogenic differentiation through downregulation of PPAR γ pathway. Effects of
45 stomatin on PPAR γ involved ERK signaling; however, an alternate pathway also exist.
46 Amongst various anti-obesity measures, stomatin serves as another potential
47 therapeutic target.

48 **Introduction**

49 Stomatin is an ancient, widely expressed, oligomeric, monotopic integral membrane
50 protein that is associated with cholesterol-rich membrane microdomains/lipid rafts.
51 Besides being a major component of the lipid raft, functions of stomatin are largely
52 unclear. The gene was first identified as the causal factor of Overhydrated Hereditary
53 Stomatocytosis (OHSt) disease, and was therefore named “stomatin”^{1,2}. However,
54 stomatin knockout mouse was viable and did not show stomatocytosis³. Human
55 stomatin is ubiquitously expressed; high expressions are noted in adipose tissues,
56 bone marrow and placenta (Supplemental Fig. 1). In placenta, stomatin plays an
57 important role in trophoblast differentiation⁴; and in bone, stomatin promotes
58 osteoclastogenesis⁵. At the cell level, stomatin is associated with the plasma
59 membrane and cytoplasmic vesicles, such as endosomes⁶, lipid droplets (LDs)⁷, and
60 specialized endosomes/granules in hematopoietic cells⁸. We have previously
61 reported that stomatin, with its unique molecular topology, promoted cell-cell fusion by
62 forming molecular assembly that recruited fusogenic protein to the appositional
63 plasma membranes⁵. In addition to the regulations of fusion events, stomatin can also
64 interact with various plasma membrane proteins residing within lipid raft and modulate

65 their activities. For examples, stomatin can regulate the transport activities of Anion
66 Exchanger 1 (AE1)⁹, glucose transporter (GLUT1)¹⁰ and water channel aquaporin-1
67 (AQP1)¹¹, or activity of acid-sensing ion channel (ASIC) family^{12, 13, 14}. Whether such
68 regulations are mediated by stomatin's scaffolding effects that change the biophysical
69 properties of the lipid rafts or by direct protein-protein interactions between stomatin
70 and the effector molecules, are currently unknown. It is also unclear if and how
71 stomatin is involved in signal transduction which is initiated by complex protein–protein
72 interactions between ligands, receptors and signaling molecules that may occur in the
73 vicinity of lipid rafts. It has been speculated that the size and composition of lipid rafts
74 could change in response to intra- or extracellular stimuli; such changes might favor
75 specific protein–protein interactions and activate corresponding signaling cascades.
76 In this study, we addressed the roles of stomatin in adipocyte differentiation and
77 functions, focusing on intracellular vesicular fusion among LDs, fatty acid uptake and
78 their associated signal transduction.

79

80 Obesity, resulting from a positive energy balance between energy harvest and energy
81 expenditure^{15, 16}, is a prevalent global healthcare problem that continues to increase
82 in countries around the world¹⁷. Obesity is characterized by increased adipose tissue
83 mass that has been associated with a strong predisposition towards metabolic
84 diseases such as diabetes, cardiovascular diseases, non-alcoholic fatty liver diseases
85 and some cancers^{18, 19, 20}. The expansion of adipose depots, especially the white
86 adipose tissues, are characterized either by the increase in adipocyte size
87 (hypertrophy) or by the formation of new adipocytes from precursor differentiation in
88 the process of adipogenesis (hyperplasia). Genetic and behavioral attributors both
89 contribute to obesity-related energy imbalance^{21, 22}. In the presence of excessive
90 energy, mature adipocytes increase in cell size and undergo cellular hypertrophy to
91 store the surplus fat²³.

92

93 Hypertrophic adipose morphology is positively associated with insulin resistance,
94 diabetes and cardiovascular disease. The hypertrophic adipocytes are ultimately
95 responsible for dysfunction of lipid homeostasis, along with other pathological
96 consequences²⁴. Hypertrophic adipocytes are characterized by excessive growth of
97 LDs; the resulting unilocular LD may occupy more than 90% of the cell volume²⁵. The

98 growth of LDs is achieved by incorporation of triacylglyceride (TG) that is synthesized
99 either locally on the surface of LDs ²⁶, or obtained from the endoplasmic reticulum ²⁷.
100 Since fatty acid (FA) is the primary energy source assimilated by adipocytes during
101 lipogenesis, measurements of FA uptake are indicative of LD growth ^{28, 29}. LDs can
102 also grow via fusion of small LDs ³⁰. Previous studies have shown that several surface
103 proteins of LDs were involved in controlling the LD size in adipocytes. For examples,
104 Perilipin (Plin1), a member of PAT family proteins highly expressed in adipocytes,
105 could regulate the lipolysis functions ^{31, 32}. The cell death-inducing DNA fragmentation
106 factor alpha (DFFA)-like effector (CIDE) family proteins, Cidea, and Fsp27/Cidec, also
107 functioned as LDs size regulators ^{33, 34}. Cooperative interactions of Plin1 and Fsp27
108 enhanced lipid transfer and LD growth ³⁵.

109

110 Adipogenesis is the process by which adipose tissues expand through hyperplastic
111 growth and differentiation. The formation of new adipocytes from precursor cells
112 enhance the capacity of energy storage. Adipogenesis is characterized by
113 expressions of C/EBP β and C/EBP δ , followed by C/EBP α and PPAR γ . The master
114 transcription regulator PPAR γ controls a variety of genes involved in adipogenesis ³⁶.
115 ³⁷. Previous studies have shown that activation of MAPK/ERK pathway (also known
116 as the Ras-Raf-MEK-ERK pathway) could down-regulate transcriptional activity of
117 PPAR γ ^{38, 39} and inhibit adipocyte differentiation.

118

119 Approaches aimed at increasing adipogenesis over adipocyte hypertrophy are now
120 regarded as a means to treat metabolic diseases. Notably, adipocyte expansion
121 through adipogenesis could mitigate the negative metabolic effects of obesity,
122 although the mechanisms and regulators are not fully understood ⁴⁰. This study
123 addressed cell biology and signaling pathways of adipocyte-like cells affected by
124 stomatin and provide insight into the control of adipogenesis and hypertrophic
125 adipocytes related to obesity.

126

127 **Results**

128 ***Expressions of Stomatin increased during adipogenic differentiation***

129 A cell model for adipogenic differentiation was established⁴¹. Treating murine 3T3-L1
130 fibroblasts with MDI cocktail for three days (day0 ~ day3), followed by insulin treatment
131 (day3 ~ day7), rendered the cells to differentiate into adipocytes-like cells, as
132 evidenced by lipid accumulation visualized and quantified by Oil Red O staining (Fig.
133 1A). Western blotting assays demonstrated that the expression of stomatin, as well as
134 major adipogenic proteins, such as PPAR γ , C/EBP α , and Perilipin, progressively
135 increased during adipogenesis (Fig. 1B). After 7-day differentiation, mature adipocytes
136 containing large lipid droplets (LD) were noted under DIC microscopy and stained
137 positive with Oil Red O. Immunofluorescence staining revealed subcellular
138 distributions of stomatin mainly on the vesicular membranes of LDs, colocalized with
139 perilipin proteins (Fig. 1C).

140 ***High expressions of Stomatin enhanced LD growth***

141 To understand the roles of stomatin in adipogenic differentiation, we over-expressed
142 human stomatin gene (hSTOM) in murine 3T3-L1 cells. After chemically induced
143 differentiation, we found that the levels of lipid accumulation and adipogenic proteins
144 were very similar in cells having excessive exogenous stomatin proteins, compared to
145 the control (Fig. 2A-B). However, when measuring the size of individual LDs, we
146 noticed that there were more large-sized LDs in cells expressing hSTOM than the
147 control (Fig. 2C), indicating that stomatin were involved in LD growth, or large LD
148 formation. Such dynamics of LDs could result from either fusion of small LDs into a
149 large one (exemplified by Supplemental Video 1 that captures the sequence of a LD-
150 LD fusion event), or from exchanges of lipid content between interacting LDs.

151

152 Since small LD vesicles were not discernible under light microscopy, we employed
153 fluorescence recovery after photobleaching (FRAP) experiments to investigate LD
154 activities. As shown in Fig. 2E, photobleaching the fluorescent lipid content of a LD
155 resulted in a fast recovery of fluorescence, reaching half of the original intensity in 15
156 min in cells over-expressing stomatin compared to a very slow recovery, reaching less

157 than 8% of original intensity in 15 min, in the control cells. These results indicate an
158 active role of stomatin in facilitating dynamic interactions between LDs.

159 ***Highly abundant Stomatin facilitates fatty acid uptake both in vitro and in vivo***

160 The process of lipid biogenesis, or lipogenesis, starts with either de novo synthesis,
161 or fatty acid uptake from extracellular environment using various fatty acid transporters
162 ⁴². In the experimental assay shown in Fig. 2F, fluorescently labeled palmitic acid
163 analogs, BODIPY-C16, when added to the culture medium, were internalized into the
164 cells and quantified continuously using an ELISA reader. Cells having high abundance
165 of stomatin exhibited more and faster fatty acid uptake compared to the control.
166 Moreover, *in vivo* fatty acid uptake experiments were performed in STOM transgenic
167 (STOM Tg) mice. BSA-emulsified BODIPY-C16 were injected into tail vein; after 15
168 min, there were much more fluorescence signals found in the adipose tissues of STOM
169 Tg than the control mice (Fig. 3F).

170 ***High expressions of Stomatin caused obesity in mice fed with high-fat diet***

171 We generated STOM transgenic (STOM Tg) mice by engineering human stomatin
172 gene into the animal. These mice contained high amount of hSTOM proteins in
173 subcutaneous white adipose tissues, distributed mainly on the surfaces of white
174 adipocytes (Fig. 3A-B). STOM Tg and the control wild-type (WT) mice were fed either
175 regular chow diet (CD), or high-fat diet (HFD) beginning at 3 weeks of age; the mice
176 were weighed every week. We noticed that body weight gains were about the same
177 comparing STOM Tg with WT mice fed with CD. When fed with HFD, however, mice
178 having up-regulated STOM gene gained more weights more rapidly than their WT
179 littermates (Fig. 3C-D). After 20 weeks, body weights of HFD-fed STOM Tg were at
180 least 20% higher than WT. Whole-body composition measurements showed that the
181 increase of fat was more significant than increases of lean, free fluid or total water (Fig.
182 3E).

183 ***HFD-fed STOM Tg mice exhibited adipocyte hypertrophy, impaired metabolisms 184 and hepatic dysfunctions***

185 After 20-week HFD feeding, mice having up-regulated STOM gene showed significant
186 increase in subcutaneous adipose tissue (SAT) and brown adipose tissue (BAT) than

187 WT, whereas mass of visceral adipose tissue (VAT) were about the same (Fig. 4A).
188 Adipocytes from SAT of HFD-fed STOM Tg mice appeared hypertrophic; they were
189 larger in size than those of WT littermates by histogram analyses (Fig. 4B). In addition,
190 Western blotting of 3T3-L1 adipocyte-like cells showed that enzymes for lipolysis,
191 including perilipin and hormone-sensitive lipase (HSL) and its various serine-
192 phosphorylated forms, were similar in cells having over-expressed hSTOM and control
193 cells (Supplemental Fig. 2A), indicating that the observed adipocyte hypertrophy
194 caused by stomatin was not due to impaired triglyceride metabolism.

195

196 The observed obesity was not a result of altered energy expenditure or energy
197 substrate selection, as evidenced by similar respiratory exchange rates comparing
198 HFD-fed STOM Tg mice and their littermate controls (Supplemental Fig. 2B). The
199 calculated heat production during the light-dark cycle showed that HFD-fed STOM Tg
200 mice had only slightly higher heat production which was too little to influence obesity
201 progression (Supplemental Fig. 2C).

202

203 Biochemical analysis after 20-week HFD feeding showed that total cholesterol (TCHO)
204 of HFD-fed STOM Tg were slightly higher than the control, but triglycerides (TG) levels
205 were the same (Supplemental Fig. 2D). Interestingly, although fasting blood glucose
206 were similar between the groups, plasma insulin and insulin resistance measured by
207 HOMA-IR experiments, and glucose tolerance measured by intraperitoneal glucose
208 tolerance test (IPTGG) were much higher and intolerable in STOM Tg than WT mice
209 (Fig. 4C). These results indicated that HFD-fed, STOM Tg aggravated glucose
210 homeostasis by enhancing insulin resistance.

211

212 Obesity is usually correlated with ectopic fat accumulation in the liver. Indeed, HFD-
213 fed STOM Tg possessed not only larger liver mass (hepatomegaly), but also exhibited
214 phenotypes of macro- and microvesicular steatosis. The observed hepatic steatosis
215 appeared to affect liver functions, as evidenced by elevated levels of plasma GPT and
216 GOP in HFD-fed STOM Tg mice (Fig. 4D).

217 **Knockdown of STOM inhibited adipogenesis and LD growth**

218 Knockdown of STOM expression was done by short hairpin RNA (shRNA) method.
219 Two shRNAs designed to target different sites of murine stomatin were separately
220 packaged into lentiviral particles and introduced into 3T3-L1 cells, resulting in
221 shSTOM-1 and shSTOM-2 cells. Both shRNAs could effectively down-regulate
222 stomatin expressions. Knocking-down STOM expression inhibited not only
223 adipogenesis, evidenced by lack of lipid accumulation (Fig. 5A) and inhibitions of
224 genes involved in adipocytic differentiation, such as PPAR γ and C/EBP α (Fig. 5B).
225 Knockdown of STOM also inhibited LD growth. As shown by Fig. 5C, histogram
226 analyses of LD sizes revealed more small-LD and fewer large-LD following STOM
227 knockdown.

228
229 Differential expressions of shSTOM-1 and control cells were analyzed after induction
230 of adipogenic differentiation for seven days by the microarray method. A total of 1478
231 annotated coding genes were identified from the transcriptomes by a stringent
232 threshold of P value < 0.05 and FDR P value < 0.001. Among them, 379 transcripts
233 were of significant difference between Stom-deficient and control cells (fold change \geq
234 3, or \leq -3); 185 of them were up-regulated and 194 down-regulated by inhibition of
235 stomatin expression (Supplemental Fig. 3A). The global view of these genes was
236 constructed by hierarchical clustering to characterize changes across six samples
237 (Supplemental Fig. 3B). These genes were mapped onto 128 Wikipathways using
238 Transcriptome Analysis Console (TAC). As the top-ranking enriched pathways
239 shown (Fig. 5D), adipogenesis genes were the most profoundly inhibited gene groups,
240 followed by PPAR signaling pathway. In the “adipogenesis genes” pathway, 12 genes
241 involved in this pathway showed significant changes; 9 of them (75%) were down-
242 regulated and 3 (25%) were up-regulated (Fig. 5E). To further validate the results, we
243 performed qPCR experiments for *Pparg* and *Cebpa* genes and confirmed
244 transcriptomic findings (Fig. 5F).

245 **Somatin inhibitor OB-1 affected adipogenic differentiation and inhibited LD** 246 **growth**

247 By inhibiting self-association, OB-1 is an effective inhibitor of stomatin-mediated
248 functions⁴³. LD₅₀ for OB-1 in 3T3-L1 cells was first determined (Fig. 6A). Drug

249 treatments using 25 μ M OB-1, while maintaining good cell viability, inhibited
250 adipogenic differentiation in a dose-dependent manner as evidenced by decreased
251 lipid accumulation (Fig. 6B). Treating 3T3-L1 cells during adipocytic differentiation with
252 OB-1 also inhibited LD growth; histogram analyses of LD sizes were applied to
253 quantify the increase of small LDs and decrease of large LDs (Fig. 6C).

254 ***Stomatin modulated adipocyte differentiation through ERK pathway***

255 Inhibitions of stomatin by either shRNA (Fig. 5A) or OB-1 (Fig. 6B) could effectively
256 block lipid accumulation by adipocytic 3T3-L1 cells. Using Western blotting assays,
257 we analyzed their effects on other adipogenesis-related genes and signaling pathways
258 (Fig. 7). Both stomatin-deficient shSTOM-1 and shSTOM-2 cells exhibited decreased
259 PPAR γ protein. While the Akt pathway was not affected by STOM knockdown, the
260 ERK pathway appeared activated as evidenced by the increased level of
261 phosphorylated ERK (*arrow*, Fig. 7A). OB-1 treatment also caused increase of
262 phospho-ERK (Fig. 7D).

263

264 Two early adipogenesis genes, C/EBP β and C/EBP δ , are upstream of PPAR γ
265 regulation. After induction of adipogenic differentiation, C/EBP β and C/EBP δ ,
266 exhibited a transient increase in the first three days, followed by a gradual decrease
267 from day 3 to day 7 (Fig. 7B and 7C, respectively). Knockdown of stomatin had little
268 effect on the protein levels and degrees of C/EBP β phosphorylation (data not shown);
269 in contrast, inhibition of stomatin was able to maintain C/EBP δ expression at much
270 higher level than the control (Fig. 7B-C).

271

272 Since activation of ERK pathway has been shown to inhibit PPAR γ ⁴⁴, we examined
273 whether stomatin positively regulated PPAR γ regulation via inhibition of pERK (*red*
274 *arrows*, Fig. 8). To this end, we treated shSTOM-1 cells with U0126, a highly selective
275 inhibitor for ERK, under the notion that U0126 might mitigate the stomatin-knockdown
276 effect of pERK activation. However, we found that U0126 treatment could not reverse
277 the lipogenesis-deficit phenotype of hSTOM-1 cells (Fig. 7E). In contrast, treating
278 hSTOM-1 cells with troglitazone (TGZ), a PPAR γ agonist, was able to partially rescue
279 lipogenesis-deficit of hSTOM-1 cells; and interestingly, dual treatments of U0126 and
280 TGZ were noted to further recover lipid accumulation (Fig. 7F). These results suggest

281 the presence of a currently unknown mechanism for stomatin to positively regulate
282 PPAR γ and activate adipogenesis (*black arrows*, Fig. 8); this unknown pathway may
283 work synergistically with the ERK pathway.

284 **Discussion**

285 We propose a working model for the roles of stomatin in adipogenic differentiation and
286 lipogenesis (Fig. 8). Along the differentiation process from undifferentiated progenitor
287 cells to immature adipocytes then to mature adipocyte, expression of stomatin
288 progressively increase. C/EBP β and C/EBP δ exhibits a transient increase during the
289 early phase, while C/EBP α in the later phase. The various adipogenic genes and
290 signaling processes seem to converge onto the PPAR γ pathway, which is considered
291 one of the master regulators of adipocyte differentiation³⁷. We report a novel finding
292 that knockdown of stomatin was able to activate ERK signaling as evidenced by the
293 increase of pERK. Since pERK is a well-known negative regulator of PPAR γ we
294 wonder if the promoting effect of stomatin on PPAR γ and the downstream adipogenic
295 phenotype is mediated through downregulation of pERK (*red arrows*, Fig. 8, see also
296⁴⁴). Our results (Fig. 7E-F), however, did not support this notion. Unlike activation of
297 PPAR γ , activation of ERK pathway alone did not rescue the lipogenesis deficit caused
298 by stomatin knockdown. This suggests the presence of another currently unknown
299 pathway (*black arrow*, Fig. 8) that may work synergistically with ERK pathway to
300 activate PPAR γ and by doing so promote adipogenesis and lipogenesis.

301
302 What signaling events are affected by stomatin which serves a major role as a
303 component of lipid rafts? Through transcriptome and pathway analyses, we identified
304 MAPK signaling as a potential pathway affected by stomatin (Fig. 5D-E and
305 supplemental Fig. 3). In the case of adipocyte differentiation, EGFR is one of the
306 upstream receptor tyrosine kinases (RTKs) for MAPK signaling. RTKs control many
307 fundamental cell behaviors by activating a series of downstream signaling pathways
308 including RAS-RAF-MEK-ERK pathway or AKT-PI3K-mTOR pathway^{45, 46}. We found
309 that the RAS-RAF-MEK-ERK pathway is involved in stomatin-mediated adipogenic
310 differentiation (Fig. 7A). Also, EGFR metabolism is highly regulated by lipid-raft
311 mediated internalization, recycling and degradation^{47, 48, 49, 50}. Increased expression of
312 stomatin, for example, caused a reduction in EGFR on the plasma membrane

313 (unpublished data), resulting in reduced ERK activity which is necessary for adipocyte
314 differentiation ⁴⁵.

315

316 Besides participating in modulation of signaling during adipogenic differentiation,
317 stomatin also plays a crucial role in LD growth characterized by vesicle enlargement
318 and transformation from multilocular LDs to unilocular LDs typically seen in adipose
319 tissues. LD is a universal cellular organelle that responds to lipid storage. It is believed
320 to be generated from the endoplasmic reticulum (ER) ⁵¹ and can enlarge through the
321 incorporation of lipid from the ER ⁵², the local synthesis of triacylglycerols (TAGs) ²⁶,
322 ⁵³, and the fusion of multiple lipid droplets ⁵⁴. Stomatin, as a LD-associated protein ⁷
323 and a major lipid raft component, could play multiple roles in growth of LD. First,
324 stomatin if present in high abundance could promote formation of potential fusion
325 pores that leads to LD fusion^{4, 5}. Second, stomatin could recruit fusion facilitators to
326 LD-LD contact site (LDCS), and by doing so regulate LD-fusion and growth. Third,
327 stomatin could help generate passage tunnels that allow lipid exchange among
328 contacted LDs ^{35, 55}. Due either to illumination toxicity to the cell or the fact that the
329 majority LD undergoing fusion were of submicron-sized, direct imaging of fusion
330 between micron-sized LD was hard to achieve under light microscopy. We therefore
331 employed FRAP experiments to address the third mechanism. Lipids in the smaller
332 LDs of the contacted pair are transferred to the larger LDs, owing to the internal
333 pressure difference, thus resulting in the fusion and growth of LDs.

334

335 For the aforementioned second mechanism, we have previously reported that
336 stomatin works as an "enhancer" on the plasma membrane to increase the
337 effectiveness of molecular machinery for membranes fusion^{4, 5}. Within a lipid raft, for
338 example, stomatin can restrict existing fusogenic effectors to the sites of membrane-
339 membrane contact and enhance their interactions. The same mechanism may apply
340 to intracellular inter-vesicular fusions. Locally enriched stomatin and perilipin can
341 recruit cell death-inducing DFF45-like effector (CIDE) family proteins to LDCS ³⁵. As
342 CIDE family proteins are crucial regulators of LD-fusion ⁵⁶, the "fencing" mechanism
343 by stomatin can promote fusion pore expansion at LDCS, resulting in LD fusion and
344 growth.

345

346 The ability of adipocyte to uptake fatty acid of superfluous lipids from the extracellular
347 environment is impacted by their physiological functions in energy homeostasis. The
348 amount and rate of fatty acid uptake were noted to increase in the presence of high
349 level stomatin both *in vitro* and *in vivo*. Although some fatty acids can cross plasma
350 membrane by passive diffusion⁵⁷, most fatty acid uptake is mediated by membrane-
351 associated transporters; many of them reside and function in the lipid rafts. When
352 bound to long-chain fatty acid (LCFAs), FAT/CD36 may partition into lipid rafts to
353 accelerate the translocation of LCFAs^{28, 58}. In lipid rafts, stomatin can function as an
354 anchor or organizer for these cholesterol-rich membrane domains. Stomatin can also
355 modulate the function of effector residing within lipid rafts. For example, stomatin can
356 regulate several ion channels activities^{59, 60} and glucose transport GLUT1 functions¹⁰.
357 In a more general sense, stomatin can capture or trap the lateral diffusion of proteins
358 within the lipid raft or affect the interaction between ligand and receptors, and by doing
359 so, regulate the downstream signaling transduction.

360
361 Adipose tissues play a central role in regulating energy storage to protect other tissues,
362 such as the muscle and the liver, from the harmful effects of superfluous circulating
363 free fatty acid. So, fatty acid uptake and LD growth are crucial in controlling lipid
364 storage and obesity development. We demonstrated here that high levels of stomatin,
365 combined with chronic energy surplus, may lead to a hypertrophy phenotype of
366 adipocytes (the HFD-fed STOM Tg mice). The resulting limitation in fat storage
367 capacity then cause local and systemic metabolism disorders⁶¹. In a broader sense,
368 stomatin is involved in regulating various aspects of lipid homeostasis, including
369 adipocyte differentiation, lipid production, lipid storage, lipolysis and lipid secretion.
370 The finding that stomatin regulates fatty acid uptake and LD growth may provide new
371 opportunities for correcting whole-body energy disorders or energy surplus-induced
372 obesity by modulating the molecular events associated with stomatin.

373

374 **Methods**

375 ***Cell Culture and induction of adipogenic differentiation***

376 3T3-L1 murine fibroblasts, purchased from Bioresource Collection and Research
377 Center (no.60159; BCRC, Hsinchu, Taiwan), were maintained in high-glucose
378 Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % bovine
379 calf *serum* and 1% sodium pyruvate. To induce differentiation into adipocyte-like cells,
380 3T3-L1 cells were first grown to confluence. Two days after reaching confluence, the
381 medium was replaced with DMEM supplemented with 10 % fetal bovine serum (FBS)
382 containing MDI cocktail, including 0.5 mM IBMX, 0.25 μ M dexamethasone and 10
383 μ g/ml bovine insulin. After 72 hours, the medium was replaced with DMEM
384 supplemented with 10 % FBS and 10 μ g/ml bovine insulin. The medium was refreshed
385 every other day. Human embryonic kidney (HEK) 293T cells were cultured in DMEM
386 supplemented with 10 % FBS.

387 ***Lentivirus production and transduction***

388 Lenti-Vector pLAS2W.puro, shRNA for *Stom* vectors (shSTOM-1: clone number
389 TRCN0000112911 and shSTOM-2: clone number TRCN 0000112912) and packaging
390 plasmids pCMV delta R8.91 and PMD.G were obtained from National RNAi
391 Core Facility Platform (Academic Sinica, Taiwan). RFP, hSTOM-RFP and hSTOM-
392 flag (hSF) were amplified from expression plasmids and cloned into the lenti-Vector.
393 HEK-293T cells were co-transfected with lentivector and packaging plasmids using
394 NTR II Non-liposome transfection reagent II (T-Pro-Biotechnology, Taiwan). The
395 supernatants containing lentivirus were harvested after 24- and 48-hr and centrifuged
396 at 1,250 rpm for 5 min to exclude any remaining HEK-293T packaging cells.
397 Subsequently, cells were transduced with the lentivirus-containing supernatants for 24
398 hrs, followed by 3 μ g/mL puromycin selection for 3 days.

399 ***Quantifications of lipid accumulation***

400 Oil Red O stock solution was prepared by dissolving 0.35g Oil Red O (no. O0625,
401 Sigma Aldrich) in 100ml pure isopropanol. Cells were fixed with 3.7% formaldehyde
402 for 1 hr at room temperature, followed by two times wash, then dried entirely using a
403 hairdryer. Post-fixed cells were stained with Oil Red O, diluted in distilled water (6:4)

404 for 1 hr at room temperature, further washed four times with distilled water. The stained
405 dyes in lipid droplets were extracted with pure isopropanol and absorbance at 490 nm
406 (OD 490) was measured.

407 ***Western blot analysis***

408 Cultured cells were washed twice with cold PBS, then lysed using RIPA lysis buffer
409 supplemented with cOmplete™ (EDTA-free Protease Inhibitor Cocktail) and
410 PhosSTOP™ (both from Sigma Aldrich). The amount of total extracted proteins was
411 quantified using Pierce 660nm protein assay reagent (Thermo Fisher Scientific™).
412 The protein lysates were separated by SDS-PAGE, then transferred onto PVDF
413 membranes. The membranes were blocked with 5% bovine serum albumin (BSA) in
414 TBS-T (Tris-buffer saline supplement with 0.1% Tween 20) at room temperature for 1
415 hr, and then incubated with primary antibodies, such as anti- STOM (a166623b,
416 Abcam), anti-perilipin (9349, Cell Signaling), anti- PPAR γ (2435, Cell Signaling), anti-
417 C/EBP α (8178, Cell Signaling), anti-human STOM (M-14, Santa Cruz Biotechnology),
418 anti- β Tubulin (T2200, Sigma Aldrich), and anti- α Actin antibodies, at 4 °C overnight.
419 After washing three times with TBS-T, the PVDF membranes were incubated with
420 horseradish peroxidase-conjugated secondary antibodies for 1 hr at room temperature,
421 then treated with substrates (SuperSignal West Femto Maximum Sensitivity Substrate,
422 Thermo Fisher Scientific), then visualized by ImageQuant (GE Healthcare Life
423 Science).

424 ***Immunofluorescence***

425 Cells seeded on coverslips were fixed with 3.7% paraformaldehyde (Sigma-Aldrich) at
426 room temperature for 15 min, rinsed twice with PBS for 5 min, permeabilized and
427 blocked using extraction buffer composed of 0.1 % saponin (Sigma-Aldrich) and 1 %
428 BSA in PBS, for 1hr. Cells were then incubated with primary antibodies, including anti-
429 STOM (a166623b, Abcam) and anti-perilipin (GT2781, GeneTex), at 4 °C overnight.
430 After washing three times with wash buffer (PBS with 0.1 % saponin), cells were
431 incubated with fluorochrome-conjugated secondary antibodies for 1 hr, and observed
432 under a confocal microscope (LSM700, Zeiss).

433 **FRAP assay**

434 Adipocyte-like 3T3-L1 cells were incubated with 6 μ M of BODIPY[™]-FL-C₁₂ (D3822,
435 Invitrogen[™]) at 37°C overnight. After refreshing with complete medium, live cells were
436 viewed under a confocal microscope (Zeiss, LSM700) using a 100x oil immersion
437 objective. Selected regions were first bleached with 15 pulses of 100% laser power
438 (combined 488 with 405 diode lasers), followed by time-lapse recording at 30-sec
439 interval using normal imaging laser power.

440 **Fatty acid uptake assay**

441 For *in vitro* analysis, adipocyte-like 3T3-L1 cells were serum-starved in serum-free
442 DMEM containing 1% sodium pyruvate for 1 hr at 37°C/5% CO₂, changed to serum-
443 free DMEM containing 1% sodium pyruvate and 10 μ g/ml insulin for 30 min, then to
444 1X HBSS containing 20mM HEPES. Subsequently, 0.2 μ M BODIPY-FL-C₁₆ (Thermo)
445 was added. The fluorescence (excitation: 485 nm and emission: 515 nm) was detected
446 by ELISA reader (TECAN) using bottom-read mode and kinetic reading at a 30-sec
447 interval. For *in vivo* analysis, 400 nM BODIPY[™]-FL-C₁₆ was emulsified in 65 mg/ml
448 BSA solution to prepare the probe solution. An amount of 1.2~1.5 ml (6~8% of body
449 weight) probe solution was injected into the animal via tail vein. The mice were
450 sacrificed and subcutaneous adipose tissues were resected for quantifications of
451 fluorescence. Fat pads were homogenized using homogenizer (Roche MagNA Lyser
452 Benchtop Homogenizer) for 45-sec at 3,000 r.p.m., and incubated at 65 °C for 30 min.
453 After centrifugation at 12,000rpm for 10 min, fat layer was collected and subjected to
454 fluorescence signal quantifications.

455 **STOM transgenic mice and phenotype analyses**

456 Transgenic mice overexpressing human *STOM* were generated by pronuclear
457 microinjection. *STOM* was cloned into vector STOM-p1033, and RNA polymerase II
458 large subunit promoter was used to drive expression in C57BL/6 mice as described
459 previously⁵. The integration of the transgene was confirmed by PCR analysis of
460 mouse tail DNA. Three to four weeks male *STOM* Tg and wild type littermates were
461 fed with either chow diet or high-fat diet (D12492, 60 kcal% fat, Research Diets) for
462 up to 20 weeks under free-feeding conditions. All of the mice were housed on a 12-hr
463 light/dark cycle at 22°C. The blood biochemistry of *STOM* Tg and WT mice were

464 examined: fasting blood glucose and plasma insulin was determined by human blood
465 glucose meter (Accu-chek Performa, Roche) and Mouse Ultrasensitive Insulin ELISA
466 (80-INSMSU-E01, ALPCO), respectively. GOT and GPT were measured using
467 Automated Clinical Chemistry Analyzer (FUJI DRI-CHEM 4000i).

468 ***Glucose tolerance tests***

469 Mice fasted overnight were injected intraperitoneally with glucose solution (1 g/kg body
470 weight). Blood glucose levels were measured at 0, 15, 30, 60, and 120 min after
471 injection using a glucometer.

472 ***Histological analyses***

473 The liver and adipose tissues were formalin-fixed and paraffin-embedded. Sections of
474 WAT and the liver were stained with hematoxylin and eosin (H&E stain). All tissue
475 images were obtained using the Aperio CS2 Digital Pathology Scanner (Leica) and
476 analyzed via Imagescope software. The size of adipose cells was analyzed using the
477 Fiji Adiposoft software to obtain the area of each and individual adipocyte.

478 ***Transcriptome expression analyses***

479 Total RNA were extracted from cells using TRIzol® reagent and subjected to global
480 transcriptome analysis using Mouse Genome Arrays (MTA-1_0, Affymetrix). The
481 Transcriptome Analysis Console (TAC4.0) was used to process and analyze CEL files.
482 We initially filtered for 11,264 probe sets annotated as locus type “coding”.
483 Subsequently, 1,478 annotated coding genes were identified via exclusively a
484 stringent threshold of $p\text{-value} < 0.05$ and $FDR\ p\text{-value} < 0.001$. Additionally, we further
485 filtered for 379 genes via exclusively a stringent fold change threshold ≥ 3 , or ≤ -3 .
486 The results were confirmed using qRT-PCR. The cDNAs were generated using
487 SuperScript III First-Strand Synthesis System following the manufacturer’s protocol.
488 To determine the expression of specific genes, quantitative real-time PCR (qRT-PCR)
489 was performed using diluted cDNA in a total volume of 5ul with SYBR Green (Qiagen).
490 Gene expression was normalized to the internal reference gene *Nono*, followed by
491 calculation using $\Delta \Delta CT$ method.

492

493

494 **References**

- 495 1. Gallagher PG, Forget BG. Structure, organization, and expression of the human band 7.2b
496 gene, a candidate gene for hereditary hydrocytosis. *The Journal of biological chemistry* **270**,
497 26358-26363 (1995).
- 498
- 499 2. Fricke B, *et al.* The "stomatin" gene and protein in overhydrated hereditary stomatocytosis.
500 *Blood* **102**, 2268-2277 (2003).
- 501
- 502 3. Zhu Y, *et al.* Stomatocytosis is absent in "stomatin"-deficient murine red blood cells. *Blood*
503 **93**, 2404-2410 (1999).
- 504
- 505 4. Chen TW, Liu HW, Liou YJ, Lee JH, Lin CH. Over-expression of stomatin causes
506 syncytium formation in nonfusogenic JEG-3 choriocarcinoma placental cells. *Cell biology*
507 *international* **40**, 926-933 (2016).
- 508
- 509 5. Lee JH, *et al.* Lipid raft-associated stomatin enhances cell fusion. *FASEB journal : official*
510 *publication of the Federation of American Societies for Experimental Biology* **31**, 47-59
511 (2017).
- 512
- 513 6. Snyers L, Umlauf E, Prohaska R. Association of stomatin with lipid-protein complexes in
514 the plasma membrane and the endocytic compartment. *European journal of cell biology* **78**,
515 802-812 (1999).
- 516
- 517 7. Umlauf E, Csaszar E, Moertelmaier M, Schuetz GJ, Parton RG, Prohaska R. Association of
518 stomatin with lipid bodies. *The Journal of biological chemistry* **279**, 23699-23709 (2004).
- 519
- 520 8. Mairhofer M, Steiner M, Mosgoeller W, Prohaska R, Salzer U. Stomatin is a major lipid-
521 raft component of platelet alpha granules. *Blood* **100**, 897-904 (2002).
- 522
- 523 9. Genetet S, Desrames A, Chouali Y, Ripoche P, Lopez C, Mouro-Chanteloup I. Stomatin
524 modulates the activity of the Anion Exchanger 1 (AE1, SLC4A1). *Scientific reports* **7**, 46170
525 (2017).
- 526

- 527 10. Montel-Hagen A, *et al.* Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals
528 unable to synthesize vitamin C. *Cell* **132**, 1039-1048 (2008).
529
- 530 11. Rungaldier S, Oberwagner W, Salzer U, Csaszar E, Prohaska R. Stomatin interacts with
531 GLUT1/SLC2A1, band 3/SLC4A1, and aquaporin-1 in human erythrocyte membrane
532 domains. *Biochimica et biophysica acta* **1828**, 956-966 (2013).
533
- 534 12. Brand J, *et al.* A stomatin dimer modulates the activity of acid-sensing ion channels. *The*
535 *EMBO journal* **31**, 3635-3646 (2012).
536
- 537 13. Klipp RC, Cullinan MM, Bankston JR. Insights into the molecular mechanisms underlying
538 the inhibition of acid-sensing ion channel 3 gating by stomatin. *J Gen Physiol* **152**, (2020).
539
- 540 14. Moshourab RA, Wetzel C, Martinez-Salgado C, Lewin GR. Stomatin-domain protein
541 interactions with acid-sensing ion channels modulate nociceptor mechanosensitivity. *The*
542 *Journal of physiology* **591**, 5555-5574 (2013).
543
- 544 15. Schwartz MW, *et al.* Obesity Pathogenesis: An Endocrine Society Scientific Statement.
545 *Endocr Rev* **38**, 267-296 (2017).
546
- 547 16. Sandholt CH, Hansen T, Pedersen O. Beyond the fourth wave of genome-wide obesity
548 association studies. *Nutr Diabetes* **2**, e37 (2012).
549
- 550 17. James WPT. Obesity: A Global Public Health Challenge. *Clin Chem* **64**, 24-29 (2018).
551
- 552 18. Swinburn BA, *et al.* The global obesity pandemic: shaped by global drivers and local
553 environments. *Lancet* **378**, 804-814 (2011).
554
- 555 19. Wabitsch M, *et al.* Severe Early-Onset Obesity Due to Bioinactive Leptin Caused by a
556 p.N103K Mutation in the Leptin Gene. *J Clin Endocrinol Metab* **100**, 3227-3230 (2015).
557
- 558 20. Haslam DW, James WP. Obesity. *Lancet* **366**, 1197-1209 (2005).
559

- 560 21. Albuquerque D, Stice E, Rodriguez-Lopez R, Manco L, Nobrega C. Current review of
561 genetics of human obesity: from molecular mechanisms to an evolutionary perspective. *Mol*
562 *Genet Genomics* **290**, 1191-1221 (2015).
563
- 564 22. Xia Q, Grant SF. The genetics of human obesity. *Ann N Y Acad Sci* **1281**, 178-190 (2013).
565
- 566 23. McLaughlin T, *et al.* Adipose Cell Size and Regional Fat Deposition as Predictors of
567 Metabolic Response to Overfeeding in Insulin-Resistant and Insulin-Sensitive Humans.
568 *Diabetes* **65**, 1245-1254 (2016).
569
- 570 24. Haczeyni F, Bell-Anderson KS, Farrell GC. Causes and mechanisms of adipocyte
571 enlargement and adipose expansion. *Obes Rev* **19**, 406-420 (2018).
572
- 573 25. Pilch PF, *et al.* Cellular spelunking: exploring adipocyte caveolae. *J Lipid Res* **48**, 2103-
574 2111 (2007).
575
- 576 26. Kuerschner L, Moessinger C, Thiele C. Imaging of lipid biosynthesis: how a neutral lipid
577 enters lipid droplets. *Traffic* **9**, 338-352 (2008).
578
- 579 27. Yang H, Galea A, Sytnyk V, Crossley M. Controlling the size of lipid droplets: lipid and
580 protein factors. *Curr Opin Cell Biol* **24**, 509-516 (2012).
581
- 582 28. Ehehalt R, Fullekrug J, Pohl J, Ring A, Herrmann T, Stremmel W. Translocation of long
583 chain fatty acids across the plasma membrane--lipid rafts and fatty acid transport proteins.
584 *Mol Cell Biochem* **284**, 135-140 (2006).
585
- 586 29. Harder T, Scheiffele P, Verkade P, Simons K. Lipid domain structure of the plasma
587 membrane revealed by patching of membrane components. *The Journal of cell biology* **141**,
588 929-942 (1998).
589
- 590 30. Bostrom P, *et al.* SNARE proteins mediate fusion between cytosolic lipid droplets and are
591 implicated in insulin sensitivity. *Nat Cell Biol* **9**, 1286-1293 (2007).
592

- 593 31. Tansey JT, *et al.* Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis,
594 enhanced leptin production, and resistance to diet-induced obesity. *Proceedings of the*
595 *National Academy of Sciences of the United States of America* **98**, 6494-6499 (2001).
596
- 597 32. Miyoshi H, *et al.* Control of adipose triglyceride lipase action by serine 517 of perilipin A
598 globally regulates protein kinase A-stimulated lipolysis in adipocytes. *The Journal of*
599 *biological chemistry* **282**, 996-1002 (2007).
600
- 601 33. Keller P, *et al.* Fat-specific protein 27 regulates storage of triacylglycerol. *The Journal of*
602 *biological chemistry* **283**, 14355-14365 (2008).
603
- 604 34. Liu K, *et al.* Functional analysis of FSP27 protein regions for lipid droplet localization,
605 caspase-dependent apoptosis, and dimerization with CIDEA. *Am J Physiol Endocrinol*
606 *Metab* **297**, E1395-1413 (2009).
607
- 608 35. Sun Z, *et al.* Perilipin1 promotes unilocular lipid droplet formation through the activation of
609 Fsp27 in adipocytes. *Nature communications* **4**, 1594 (2013).
610
- 611 36. Yuan SM, *et al.* Over-expression of PPAR-gamma2 gene enhances the adipogenic
612 differentiation of hemangioma-derived mesenchymal stem cells in vitro and in vivo.
613 *Oncotarget* **8**, 115817-115828 (2017).
614
- 615 37. Farmer SR. Transcriptional control of adipocyte formation. *Cell Metab* **4**, 263-273 (2006).
616
- 617 38. Bost F, Aouadi M, Caron L, Binetruy B. The role of MAPKs in adipocyte differentiation
618 and obesity. *Biochimie* **87**, 51-56 (2005).
619
- 620 39. Aubert J, Belmonte N, Dani C. Role of pathways for signal transducers and activators of
621 transcription, and mitogen-activated protein kinase in adipocyte differentiation. *Cell Mol*
622 *Life Sci* **56**, 538-542 (1999).
623
- 624 40. Ghaben AL, Scherer PE. Adipogenesis and metabolic health. *Nat Rev Mol Cell Biol* **20**,
625 242-258 (2019).

626

627 41. Green H, Meuth M. An established pre-adipose cell line and its differentiation in culture.
628 *Cell* **3**, 127-133 (1974).

629

630 42. Dutta-Roy AK. Cellular uptake of long-chain fatty acids: role of membrane-associated fatty-
631 acid-binding/transport proteins. *Cell Mol Life Sci* **57**, 1360-1372 (2000).

632

633 43. Wetzel C, *et al.* Small-molecule inhibition of STOML3 oligomerization reverses
634 pathological mechanical hypersensitivity. *Nat Neurosci* **20**, 209-218 (2017).

635

636 44. Prusty D, Park BH, Davis KE, Farmer SR. Activation of MEK/ERK signaling promotes
637 adipogenesis by enhancing peroxisome proliferator-activated receptor gamma
638 (PPARgamma) and C/EBPalpha gene expression during the differentiation of 3T3-L1
639 preadipocytes. *The Journal of biological chemistry* **277**, 46226-46232 (2002).

640

641 45. Scioli MG, Bielli A, Gentile P, Mazzaglia D, Cervelli V, Orlandi A. The biomolecular basis
642 of adipogenic differentiation of adipose-derived stem cells. *Int J Mol Sci* **15**, 6517-6526
643 (2014).

644

645 46. Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.
646 *Cancers (Basel)* **9**, (2017).

647

648 47. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. Clathrin-mediated
649 internalization is essential for sustained EGFR signaling but dispensable for degradation.
650 *Developmental cell* **15**, 209-219 (2008).

651

652 48. Lajoie P, Kojic LD, Nim S, Li L, Dennis JW, Nabi IR. Caveolin-1 regulation of dynamin-
653 dependent, raft-mediated endocytosis of cholera toxin-B sub-unit occurs independently of
654 caveolae. *Journal of cellular and molecular medicine* **13**, 3218-3225 (2009).

655

656 49. Lajoie P, Goetz JG, Dennis JW, Nabi IR. Lattices, rafts, and scaffolds: domain regulation
657 of receptor signaling at the plasma membrane. *The Journal of cell biology* **185**, 381-385
658 (2009).

659

660 50. Disanza A, Frittoli E, Palamidessi A, Scita G. Endocytosis and spatial restriction of cell
661 signaling. *Mol Oncol* **3**, 280-296 (2009).

662

663 51. Wilfling F, Haas JT, Walther TC, Farese RV, Jr. Lipid droplet biogenesis. *Curr Opin Cell
664 Biol* **29**, 39-45 (2014).

665

666 52. Gross DA, Zhan C, Silver DL. Direct binding of triglyceride to fat storage-inducing
667 transmembrane proteins 1 and 2 is important for lipid droplet formation. *Proceedings of the
668 National Academy of Sciences of the United States of America* **108**, 19581-19586 (2011).

669

670 53. Wilfling F, *et al.* Triacylglycerol synthesis enzymes mediate lipid droplet growth by
671 relocalizing from the ER to lipid droplets. *Developmental cell* **24**, 384-399 (2013).

672

673 54. Walther TC, Farese RV, Jr. Lipid droplets and cellular lipid metabolism. *Annu Rev Biochem
674* **81**, 687-714 (2012).

675

676 55. Yu J, Li P. The size matters: regulation of lipid storage by lipid droplet dynamics. *Sci China
677 Life Sci* **60**, 46-56 (2017).

678

679 56. Gao G, *et al.* Control of lipid droplet fusion and growth by CIDE family proteins. *Biochim
680 Biophys Acta Mol Cell Biol Lipids* **1862**, 1197-1204 (2017).

681

682 57. Simard JR, Pillai BK, Hamilton JA. Fatty acid flip-flop in a model membrane is faster than
683 desorption into the aqueous phase. *Biochemistry* **47**, 9081-9089 (2008).

684

685 58. Pohl J, Ring A, Korkmaz U, Ehehalt R, Stremmel W. FAT/CD36-mediated long-chain fatty
686 acid uptake in adipocytes requires plasma membrane rafts. *Mol Biol Cell* **16**, 24-31 (2005).

687

688 59. Lapatsina L, *et al.* Regulation of ASIC channels by a stomatin/STOML3 complex located
689 in a mobile vesicle pool in sensory neurons. *Open biology* **2**, 120096 (2012).

690

- 691 60. Price MP, Thompson RJ, Eshcol JO, Wemmie JA, Benson CJ. Stomatin modulates gating
692 of acid-sensing ion channels. *The Journal of biological chemistry* **279**, 53886-53891 (2004).
693
- 694 61. Muir LA, *et al.* Adipose tissue fibrosis, hypertrophy, and hyperplasia: Correlations with
695 diabetes in human obesity. *Obesity (Silver Spring)* **24**, 597-605 (2016).
696
697
698

699 **Acknowledgements**

700 The authors acknowledge Mouse Genome Arrays analysis provided by Genomics
701 Center for Clinical and Biotechnological Applications of Cancer Progression Research
702 Center, National Yang-Ming University. Genomics Center for Clinical and
703 Biotechnological Applications is supported by National Core Facility for
704 Biopharmaceuticals (NCFB), Ministry of Science and Technology. We thank the
705 Taiwan Mouse Clinic (TMC) from the Academia Sinica and Taiwan Animal Consortium
706 for technical support in metabolism related experiments. We are deeply grateful to Dr.
707 Kate Hua (NYMU), Chian-Feng Chen (NYMU), Tzue-Shuh Jou (NTU), Jia-Fwu Shyu
708 (NDMC) and Hong-Yu Chien (TCH) for their helpful scientific suggestions; Dr. Li-Li Li
709 (LTRI, Canada) for her helpful proof-reading of the manuscript. This work was
710 supported by the Ministry of Education, Aim for the Top University Plan: MOST 109-
711 2740-B-010-002. The authors declare no conflicts of interest. NYMU: National Yang-
712 Ming University. NTU: National Taiwan University. NDMC: National Defense Medical
713 Center. TCH: Taipei City Hospital.

714 **Author contributions**

715 S.-C. Wu, W.-N. Lian, C.-Y. Tung and C.-H. Lin designed the research; S.-C. Wu
716 and Y.-M. Lio performed the research and analyzed the data; S.-C. Wu, J.-H. Lee,
717 H.-W. Liu and T.-W. Chen contributed microscopic approaches; W.-J. Lin, C.-Y.
718 Chen and C.-Y. Yang contributed materials; and S.-C. Wu, and C.-H. Lin wrote the
719 manuscript.

720 **Competing financial interests**

721 The authors declare that no competing financial interests exist.

722

723 **Supplemental**

724 **Video 1**

725 The time-lapse recording under phase contrast and fluorescence microscopy of the
726 sequence of a LD-LD fusion event within a live adipocyte-like 3T3-L1 cell transfected
727 with hSTOM-RFP. Time is shown in hr:min.

728




Figure 1: Stomatin expressions increased during adipogenesis. **A**) Mouse 3T3-L1 fibroblasts were treated with MDI induction medium (Diff.) or control vehicle. On day 0, 3, 5, 7 after induction, cells were stained with Oil Red O and observed under microscopy. The amounts of lipid accumulation for individual culture plates were quantified by measuring absorbance at 490 nm (OD 490). Mean \pm s.d. for six independent experiments. $**P < 0.01$ and $****P < 0.0001$ by two-way ANOVA analysis. **B**) On the day after induction as indicated, Western blotting analyses revealed increased expressions of mouse stomatin (mSTOM), perilipin, PPAR γ and C/EBP α . **C**) Subcellular distributions of endogenous stomatin (green) and perilipin (red) on cells after 7-day induction were observed by DIC and immunofluorescence microscopy (IF). Cell nuclei were revealed by DNA stain (blue). Perilipin and mSTOM were found colocalized on vesicular membranes of lipid droplets (LDs) (inset). Bar = 10 μ m.




Figure 2: Overexpression of stomatin promoted lipid droplet growth and facilitated fatty acid uptake in adipocyte-like cells.

A) Mouse 3T3-L1 cells over-expressing exogenous human stomatin conjugated with RFP (hSTOM-RFP) or RFP as control, were induced to differentiate into adipocyte-like cells. Lipid contents of the cells were visualized by Oil Red O staining and OD measured at 490nm. Mean \pm s.d. for four independent experiments. **B**) Exogenous human stomatin (hSTOM), PPAR γ , C/EBP α , and perilipin were examined by Western blotting. **C**) The numbers and sizes of lipid droplets (LDs) in adipocyte-like cells (on day 7 of induction) were quantified after AdipoRed staining and plotted as a function of LD areas. There were larger LDs ($> 80 \mu\text{m}^2$) found in cells over-expressing stomatin than the control cells, which contained mostly small ($< 40 \mu\text{m}^2$) LDs. Mean \pm s.e.m. for three independent experiments. * $P < 0.05$ by paired t-test. Bar = $100 \mu\text{m}$. **D**) The time-lapse recording of a LD-LD fusion event (arrow) within a live adipocyte-like 3T3-L1 cell transfected with hSTOM-RFP. A small LD (green dashed circle) was noted to fuse with a large LD (red dashed circle) then disappeared. Time of image tiles is shown as hr : min. PC: phase-contrast microscopy; Flu: fluorescence microscopy. **E**) Fluorescence recovery after photobleaching (FRAP) experiments were done on cells expressing hSTOM-RFP ($n = 7$) or RFP ($n = 10$). Adipocyte-like cells were pre-treated with BODIPY-FL-C12 fatty acid. Photobleaching was done at a randomly selected LD (dashed box); After bleaching, fluorescence

recovery, as % of original intensity, was recorded by time-lapse microscopy at a 30-sec interval. Mean \pm s.e.m. for three independent experiments. Bar = $10 \mu\text{m}$. **F**) Adipocyte-like cells expressing FLAG-conjugated human stomatin (hSF) or vector control (V) were treated with $0.2 \mu\text{M}$ fluorescently-labeled fatty acid (BODIPY-FL-C16) to measure uptake of extracellular fatty acid into the cells, or with fluorescent tag (BODIPY-FL) as a control to measure non-specific leak of BODIPY-FL into the cell. Intracellular accumulations of fluorescence over time were recorded and plotted as a function of time. Mean \pm s.e.m. for three independent experiments.




Figure 3: Stomatin transgenic mice fed with high-fat diet were more obese than the control mice. **A)** Western blotting revealed high expression of human stomatin (hSTOM) in stomatin transgenic mice (STOM Tg). **B)** The exogenous hSTOM proteins were present mainly on surface of the adipocyte plasma membrane in fat tissues of STOM Tg mice. **C)** Body weight changes of STOM Tg and wild type (WT) mice fed with regular chow diet (CD) or high-fat diet (HFD) for 20 weeks. Representative photos of the mice are shown. **D)** Body weight increments after 20-week feeding were measured. Each dot represents one mouse. While no difference was noticed in animals fed with CD, body weight gains were significantly higher in HFD-fed STOM Tg, compared with HFD-fed WT mice. Mean \pm s.d. is shown. n.s = non-significant. $**P < 0.01$ by unpaired t-test. **E)** The mass of whole body, fat, lean, free fluid, and total water were calculated for HFD-fed STOM Tg and HFD-fed WT mice. **F)** Fatty acid uptake was measured in vivo. Fluorescently-labeled BODIPY-FL-C16 fatty acid, or BODIPY-BSA, were injected into tail vein of STOM Tg mice or WT mice. After 15 min, aqueous portions of white adipose tissue (WAT) from the animal were extracted and fluorescence signals that represented lipid uptake were quantified. Data shown are fold changes of fluorescence intensity using BODIPY-BSA injected to WT mice as the reference. Each dot represents one mouse. Mean \pm s.d. for three independent experiments. $*P < 0.05$, $**P < 0.01$, and $****P < 0.0001$ by two-way ANOVA. BODIPY-FL-C16: 4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Hexadecanoic Acid; BSA: bovine serum albumin




Figure 4: Stomatin transgenic mice fed with high-fat diet exhibited adipocyte hypertrophy and metabolism disorders. **A**) The weights of subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT) and brown adipose tissue (BAT) in stomatin transgenic mice (STOM Tg) or wild type mice (WT) fed with regular chow diet (CD) or high-fat diet (HFD) for 20 weeks were measured. **B**) Representative H&E stained histopathological sections of SAT, and BAT from HFD-fed STOM Tg or HFD-fed WT mice. Histogram analyses of sizes of adipocytes are shown. Bar = 250μm. **C**) After HFD-feeding for 20 weeks, the animal's fasting glucose, serum insulin, homeostatic model assessment of insulin resistance (HOMA-IR), and intraperitoneal glucose tolerance test (IPGTT) were examined. **D**) The mass of liver of STOM Tg or WT mice, fed with HFD for 20 weeks, were weighed. Fatty liver changes revealed by histopathological sections and high level of serum glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT) indicated impaired hepatic functions in STOM Tg mice, compared to WT mice. Bar = 100μm. Each dot represents one mouse. Mean ± s.d. is shown. n.s = non-significant. *P<0.05, **P<0.01, and ***P<0.001 by unpaired t-test.




Figure 5: Decreased stomatin expression affected adipogenesis and inhibited lipid droplet growth. **A)** Stomatin knockdown was done by transduction of shRNA of Stomatin gene into 3T3-L1 cells generating shSTOM-1 cells or shSTOM-2 cells. After induction of adipogenic differentiation, shSTOM-1 and control cells were stained with Oil Red O. Cells after 7-day induction are shown using high-power microscopy. **B)** On the day after induction as indicated, Western blotting analyses revealed decreased expression of mouse stomatin (mSTOM) by knockdown. Adipogenic proteins, including PPAR γ , and C/EBP α were also down-regulated. **C)** On day 7 of adipogenic differentiation, adipocyte-like shSTOM-1 cells were stained with AdipoRed and observed under phase-contrast (PC) and fluorescence (Flu) microscopy. The size of lipid droplets (LDs) were measured, and their number per 100 adipocytes were calculated. Histogram analyses showed more small LDs (< 40 μ m²) and fewer large (> 80 μ m²) LDs in shSTOM-1 cells than the control. Mean \pm s.d. for three independent experiments. ****P<0.0001 by two-way ANOVA. Bar = 30 μ m. **D)** Transcriptome analyses of adipocyte-like shSTOM-1 and control cells after induction for 7 days. From the data of microarray assays, scatter plots revealed enriched Wiki pathways in shSTOM-1 cells comparing to the control. For a given pathway, ratio of gene number being up- or down-regulated in that pathway were determined, and plotted as function of fold change. Each dot represents one gene. The color of the dots represents the range of P-values related to the indicated pathway. **E)** Heat map of adipogenesis gene obtained from the enrichment-based cluster analysis of the Wiki pathway. **F)** Real-time qPCR analyses to validate the changed genes revealed by microarray assays. Data shown are fold changes relative to Nono mRNA level. Mean \pm s.d. for three independent experiments. ***P<0.001 by unpaired t-test.




Figure 6: Stomatin inhibitor OB-1 inhibited adipogenesis and hindered lipid droplet growth. A) Cell viability after OB-1 treatments for 48h or 72h were tested by MTT assays. LC50 of OB-1 were calculated from three independent experiments. **B)** Culture adipocyte-like 3T3-L1 plates treated with or without OB-1 at concentrations indicated, were stained with Oil Red O and subjected to OD 490 quantifications. Note OB-1 inhibited adipogenesis in a dose-dependent manner, compared to the control DMSO treatment. Each OB-1 treatment data was normalized to the corresponding DMSO vehicle control; fold changes are shown. Mean \pm s.d. for three independent experiments (n=9 for each experiment). ****P<0.0001 by one-way ANOVA. **C)** Adipocyte-like 3T3-L1 cells after 7-day induction were treated with 25µM OB-1 or control vehicle, and stained with AdipoRed. The cells were observed under phase contrast (PC) or fluorescence microscopy (Flu) to determine the numbers and sizes of LD. Histogram analyses showed increased small LDs (< 40 µm²) and decreased large (> 80 µm²) LDs after OB-1 treatments, compared to the control. Mean \pm s.d. for three independent experiments. **P<0.01 by two-way ANOVA. Bar = 30 µm.




Figure 7: Knockdown of stomatin activated ERK-pathway. **A)** shRNA were transduced into 3T3-L1 cells to knockdown stomatin and generating shSTOM-1 and shSTOM-2 cells. After induction of differentiation, Western blotting analyses were done. Although Akt pathway remained unchanged, the ERK pathway was activated as evidenced by increased pERK (arrow). **B, C)** Expressions of early adipogenic genes, Cebpb and Cebpd, were examined at mRNA level by qPCR. **B)** Expressions of Cebpb increased in the first three days of adipogenic differentiation, and subsequently decreased. Knockdown of stomatin (exemplified by shSTOM-1 cells) did not significantly influence this pattern. **C)** Expressions of Cebpd gene also exhibited a transient early increase then declined; however, knockdown of stomatin appeared to significantly increase and maintain Cebpd expression at a relatively higher level than the control. The house-keeping Nono gene was used as the reference for qPCR exoeriments. * $P < 0.05$ by unpaired t-test. **D)** Treating adipocyte-like cells with stomatin inhibitor OB-1 also resulted in activation of ERK pathway, evidenced by increased pERK (arrow). **E)** Levels of lipogenesis by adipocyte-like 3T3-L1 cells were quantified by measuring OD 490 after Oil Red O staining. Treating shSTOM-1 cells with 10 μ M U0126, an ERK pathway inhibitor, from day3 to day 7, did not reverse the lipogenesis inhibition caused by stomatin knockdown. **F)** On the other hand, treating shSTOM-1 cells with TGZ, a PPAR γ activator, in the first three days of adipogenic differentiation, was able to partially recover the knockdown-caused lipogenesis deficit; treating shSTOM-1 cells with both TGZ and U0126 was noted to further increase lipid accumulation. Mean \pm s.d. for six independent experiments. * $P < 0.05$, and ** $P < 0.01$ by one-way ANOVA. qPCR: quantitative real-time PCR.






Figure 8: Stomatin's roles in modulating adipogenic differentiation and lipogenesis. Undifferentiated progenitor cells can be induced to undergo adipogenic differentiation to become immature adipocytes, and further develop into mature adipocytes, characterized by fatty acid uptake, production of lipid, and fusions and enlargements of lipid droplets (LDs). Dynamic expressions of adipogenic genes along this process are depicted. Stomatin progressively increases during adipocyte differentiation and maturation, and participates not only in fatty acid uptake and LD fusions, but also in modulation of adipogenic gene expressions. By inhibiting pERK, stomatin activates PPAR γ : resulting in adipocyte maturation and lipogenesis. Stomatin also plays a role in regulating early phase adipogenic genes, such as C/EBP β and C/EBP δ through currently unknown mechanisms. C/EBP: CCAAT/enhancer binding protein; PPAR γ : peroxisome proliferator-activated receptor- γ .


A





B



Supplemental Figure 1: In silico analyses of stomatin mRNA and proteins in different human tissues. **A)** The bar charts were reproduced based on the data of NCBI: <https://www.ncbi.nlm.nih.gov/gene/2040?report=expression&bioproject=PRJEB4337>, containing RNA sequencing of total RNA from 20 human tissues. Adipose tissues expressed the highest amount of mRNA among all tissues examined. Mean \pm s.d. is shown. **B)** The bar charts were reproduced using ProteomicsDB: <https://www.proteomicsdb.org/proteomicsdb/#protein/proteinDetails/54374/expression>. The error bars indicate the lowest and highest abundance level for the selected protein.



Supplemental Figure 2: Regulations of lipid metabolisms by stomatin. **A)** Hormone-sensitive lipase (HSL) and various phospho-HSL forms (ser563, ser565, and ser660) in adipocyte-like 3T3-L1 cells expressing human stomatin, or not, were examined by Western blotting analyses. No significant difference have been observed between overexpression of stomatin and the control. **B)** Energy expenditure and **C)** thermogenesis of *STOM Tg* mice and WT littermate mice after 5-month high fat diet (HFD) feeding were determined. Both measurements showed no significant difference in respiratory exchange ratio (RER) and heat production comparing *STOM Tg* with the control. **D)** Serum triglyceride and cholesterol concentrations of *STOM Tg* fed with HFD for 20 weeks exhibited no significant difference comparing to the control WT littermate mice. Each dot represents one mouse. Mean \pm s.d. is shown.

A**B**

Supplemental Figure 3: Transcriptome analyses of shSTOM-1 and control cells after induction of adipogenic differentiation. A) Scatter plots of the normalized signal intensities of 1,478 genes that exhibited differential expressions between shSTOM-1 and control cells. Log₂ intensities for each spot on the microarray are plotted on the x and y axes with signals from root tips stressed for control and shSTOM-1. The diagonal lines represent fold change cutoffs of ±3. The red spots represent up-regulated genes and the green spots indicate down-regulated genes. **B)** Hierarchical cluster analyses of the 1,478 genes shown in **A)**. Data were collected from three independent cell clones. Relative expression levels of genes are illustrated by the color gradient (Z-score).

Figures




Figure 1

Stomatin expressions increased during adipogenesis. A) Mouse 3T3-L1 fibroblasts were treated with MDI induction medium (Diff.) or control vehicle. On day 0, 3, 5, 7 after induction, cells were stained with Oil Red O and observed under microscopy. The amounts of lipid accumulation for individual culture plates were quantified by measuring absorbance at 490 nm (OD 490). Mean \pm s.d. for six independent experiments. ** $P < 0.01$ and **** $P < 0.0001$ by two-way ANOVA analysis. B) On the day after induction as indicated, Western blotting analyses revealed increased expressions of mouse stomatin (mSTOM), perilipin, PPAR γ and C/EBP α . C) Subcellular distributions of endogenous stomatin (green) and perilipin (red) on cells after 7-day induction were observed by DIC and immunofluorescence microscopy (IF). Cell nuclei were revealed by DNA stain (blue). Perilipin and mSTOM were found colocalized on vesicular membranes of lipid droplets (LDs) (inset). Bar = 10 μ m.




Figure 2

Overexpression of stomatin promoted lipid droplet growth and facilitated fatty acid uptake in adipocyte-like cells. A) Mouse 3T3-L1 cells over-expressing exogenous human stomatin conjugated with RFP (hSTOM-RFP) or RFP as control, were induced to differentiate into adipocyte-like cells. Lipid contents of the cells were visualized by Oil Red O staining and OD measured at 490nm. Mean \pm s.d. for four independent experiments. B) Exogenous human stomatin (hSTOM), PPAR γ , C/EBP α , and perilipin were

examined by Western blotting. C) The numbers and sizes of lipid droplets (LDs) in adipocyte-like cells (on day 7 of induction) were quantified after AdipoRed staining and plotted as a function of LD areas. There were larger LDs ($> 80 \mu\text{m}^2$) found in cells over-expressing stomatin than the control cells, which contained mostly small ($< 40 \mu\text{m}^2$) LDs. Mean \pm s.e.m. for three independent experiments. $*P < 0.05$ by paired t-test. Bar = $100 \mu\text{m}$. D) The time-lapse recording of a LD-LD fusion event (arrow) within a live adipocyte-like 3T3-L1 cell transfected with hSTOM-RFP. A small LD (green dashed circle) was noted to fuse with a large LD (red dashed circle) then disappeared. Time of image tiles is shown as hr : min. PC: phase-contrast microscopy; Flu: fluorescence microscopy. E) Fluorescence recovery after photobleaching (FRAP) experiments were done on cells expressing hSTOM-RFP ($n = 7$) or RFP ($n = 10$). Adipocyte-like cells were pre-treated with BODIPY-FL-C12 fatty acid. Photobleaching was done at a randomly selected LD (dashed box); Afterbleaching, fluorescence recovery, as % of original intensity, was recorded by time-lapse microscopy at a 30-sec interval. Mean \pm s.e.m. for three independent experiments. Bar = $10 \mu\text{m}$. F) Adipocyte-like cells expressing FLAG-conjugated human stomatin (hSF) or vector control (V) were treated with $0.2 \mu\text{M}$ fluorescently-labeled fatty acid (BODIPY-FL-C16) to measure uptake of extracellular fatty acid into the cells, or with fluorescent tag (BODIPY-FL) as a control to measure non-specific leak of BODIPY-FL into the cell. Intracellular accumulations of fluorescence over time were recorded and plotted as a function of time. Mean \pm s.e.m. for three independent experiments.




Figure 3

Stomatin transgenic mice fed with high-fat diet were more obese than the control mice. A) Western blotting revealed high expression of human stomatin (hSTOM) in stomatin transgenic mice (STOM Tg). B) The exogenous hSTOM proteins were present mainly on surface of the adipocyte plasma membrane in fat tissues of STOM Tg mice. C) Body weight changes of STOM Tg and wild type (WT) mice fed with regular chow diet (CD) or high-fat diet (HFD) for 20 weeks. Representative photos of the mice are shown. D) Body weight increments after 20-week feeding were measured. Each dot represents one mouse. While

no difference was noticed in animals fed with CD, body weight gains were significantly higher in HFD-fed STOM Tg, compared with HFD-fed WT mice. Mean \pm s.d. is shown. n.s = non-significant. ** $P < 0.01$ by unpaired t-test. E) The mass of whole body, fat, lean, free fluid, and total water were calculated for HFD-fed STOM Tg and HFD-fed WT mice. F) Fatty acid uptake was measured in vivo. Fluorescently-labeled BODIPY-FL-C16 fatty acid, or BODIPY-BSA, were injected into tail vein of STOM Tg mice or WT mice. After 15 min, aqueous portions of white adipose tissue (WAT) from the animal were extracted and fluorescence signals that represented lipid uptake were quantified. Data shown are fold changes of fluorescence intensity using BODIPY-BSA injected to WT mice as the reference. Each dot represents one mouse. Mean \pm s.d. for three independent experiments. * $P < 0.05$, ** $P < 0.01$, and **** $P < 0.0001$ by two-way ANOVA. BODIPY-FL-C16: 4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Hexadecanoic Acid; BSA: bovine serum albumin




Figure 4

Stomatin transgenic mice fed with high-fat diet exhibited adipocyte hypertrophy and metabolism disorders. A) The weights of subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT) and brown adipose tissue (BAT) in stomatin transgenic mice (STOM Tg) or wild type mice (WT) fed with regular chow diet (CD) or high-fat diet (HFD) for 20 weeks were measured. B) Representative H&E stained histopathological sections of SAT, and BAT from HFD-fed STOM Tg or HFD-fed WT mice. Histogram analyses of sizes of adipocytes are shown. Bar = 250 μ m. C) After HFD-feeding for 20 weeks, the animal's fasting glucose, serum insulin, homeostatic model assessment of insulin resistance (HOMA-IR), and intraperitoneal glucose tolerance test (IPGTT) were examined. D) The mass of liver of STOM Tg or WT mice, fed with HFD for 20 weeks, were weighed. Fatty liver changes revealed by histopathological sections and high level of serum glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT) indicated impaired hepatic functions in STOM Tg mice, compared to WT mice. Bar = 100 μ m. Each dot represents one mouse. Mean \pm s.d. is shown. n.s = non-significant. *P<0.05, **P<0.01, and ***P<0.001 by unpaired t-test.




Figure 5

Decreased stomatin expression affected adipogenesis and inhibited lipid droplet growth. A) Stomatin knockdown was done by transduction of shRNA of Stomatin gene into 3T3-L1 cells generating shSTOM-1 cells or shSTOM-2 cells. After induction of adipogenic differentiation, shSTOM-1 and control cells were stained with Oil Red O. Cells after 7-day induction are shown using high-power microscopy. B) On the day after induction as indicated, Western blotting analyses revealed decreased expression of mouse stomatin

(mSTOM) by knockdown. Adipogenic proteins, including PPAR γ , and C/EBP α were also down-regulated. C) On day 7 of adipogenic differentiation, adipocyte-like shSTOM-1 cells were stained with AdipoRed and observed under phase-contrast (PC) and fluorescence (Flu) microscopy. The size of lipid droplets (LDs) were measured, and their number per 100 adipocytes were calculated. Histogram analyses showed more small LDs (< 40 μm^2) and fewer large (> 80 μm^2) LDs in shSTOM-1 cells than the control. Mean \pm s.d. for three independent experiments. ****P<0.0001 by two-way ANOVA. Bar = 30 μm . D) Transcriptome analyses of adipocyte-like shSTOM-1 and control cells after induction for 7 days. From the data of microarray assays, scatter plots revealed enriched Wiki pathways in shSTOM-1 cells comparing to the control. For a given pathway, ratio of gene number being up- or down-regulated in that pathway were determined, and plotted as function of fold change. Each dot represents one gene. The color of the dots represents the range of P-values related to the indicated pathway. E) Heat map of adipogenesis gene obtained from the enrichment-based cluster analysis of the Wiki pathway. F) Real-time qPCR analyses to validate the changed genes revealed by microarray assays. Data shown are fold changes relative to Nono mRNA level. Mean \pm s.d. for three independent experiments. ***P<0.001 by unpaired t-test.




Figure 6

Stomatin inhibitor OB-1 inhibited adipogenesis and hindered lipid droplet growth. A) Cell viability after OB-1 treatments for 48h or 72h were tested by MTT assays. LC50 of OB-1 were calculated from three independent experiments. B) Culture adipocyte-like 3T3-L1 plates treated with or without OB-1 at concentrations indicated, were stained with Oil Red O and subjected to OD 490 quantifications. Note OB-1 inhibited adipogenesis in a dose-dependent manner, compared to the control DMSO treatment. Each OB-1 treatment data was normalized to the corresponding DMSO vehicle control; fold changes are shown. Mean \pm s.d. for three independent experiments (n=9 for each experiment). ****P<0.0001 by one-way

ANOVA. C) Adipocyte-like 3T3-L1/3T3-L1 cells after 7-day induction were treated with 25 μ M OB-1 or control vehicle, and stained with AdipoRed. The cells were observed under phase contrast (PC) or fluorescence microscopy (Flu) to determine the numbers and sizes of LD. Histogram analyses showed increased small LDs (< 40 μ m²) and decreased large (> 80 μ m²) LDs after OB-1 treatments, compared to the control. Mean \pm s.d. for three independent experiments. **P<0.01 by two-way ANOVA. Bar = 30 μ m.




Figure 7

Knockdown of stomatin activated ERK-pathway. A) shRNA were transduced into 3T3-L1 cells to knockdown stomatin and generating shSTOM-1 and shSTOM-2 cells. After induction of differentiation, Western blotting analyses were done. Although Akt pathway remained unchanged, the ERK pathway was activated as evidenced by increased pERK (arrow). B, C) Expressions of early adipogenic genes, Cebpb and Cebpd, were examined at mRNA level by qPCR. B) Expressions of Cebpb increased in the first three days of adipogenic differentiation, and subsequently decreased. Knockdown of stomatin (exemplified by

shSTOM-1 cells) did not significantly influence this pattern. C) Expressions of *Cebpd* gene also exhibited a transient early increase then declined; however, knockdown of stomatin appeared to significantly increase and maintain *Cebpd* expression at a relatively higher level than the control. The house-keeping *Nono* gene was used as the reference for qPCR experiments. * $P < 0.05$ by unpaired t-test. D) Treating adipocyte-like cells with stomatin inhibitor OB-1 also resulted in activation of ERK pathway, evidenced by increased pERK (arrow). E) Levels of lipogenesis by adipocyte-like 3T3-L1 cells were quantified by measuring OD 490 after Oil Red O staining. Treating shSTOM-1 cells with 10 μ M U0126, an ERK pathway inhibitor, from day3 to day 7, did not reverse the lipogenesis inhibition caused by stomatin knockdown. F) On the other hand, treating shSTOM-1 cells with TGZ, a PPAR γ activator, in the first three days of adipogenic differentiation, was able to partially recover the knockdown-caused lipogenesis deficit; treating shSTOM-1 cells with both TGZ and U0126 was noted to further increase lipid accumulation. Mean \pm s.d. for six independent experiments. * $P < 0.05$, and ** $P < 0.01$ by one-way ANOVA. qPCR: quantitative real-time PCR.




Figure 8

Stomatin's roles in modulating adipogenic differentiation and lipogenesis. Undifferentiated progenitor cells can be induced to undergo adipogenic differentiation to become immature adipocytes, and further develop into mature adipocytes, characterized by fatty acid uptake, production of lipid, and fusions and enlargements of lipid droplets (LDs). Dynamic expressions of adipogenic genes along this process are depicted. Stomatin progressively increases during adipocyte differentiation and maturation, and participates not only in fatty acid uptake and LD fusions, but also in modulation of adipogenic gene expressions. By inhibiting pERK, stomatin activates PPAR γ : resulting in adipocyte maturation and lipogenesis. Stomatin also plays a role in regulating early phase adipogenic genes, such as C/EBP β and

C/EBP δ through currently unknown mechanisms. C/EBP: CCAAT/enhancer binding protein; PPAR γ : peroxisome proliferator-activated receptor- γ .

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementalvideo1LDLDFusionmovie.mp4](#)